Company intelligence / Profile preview

ENB Therapeutics

New York City, New York, United Statesenbpharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ENB’s lead candidate (ENB‑003), a selective small molecule ETBR inhibitor, has received IND approval from the FDA and entered clinical trials in combination with pembrolizumab for patients with drug-resistant melanoma and ovarian or pancreatic cancers. Preclinical data show efficacy in multiple solid tumors by converting “cold” tumors to “hot” and promoting TLO formation. Clinical results are not yet published but early-stage trials are ongoing.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

5 assets

ENB-003

4 more assets in the full pipeline.

Request access →

Partnerships

MerckAvestria VenturesAlexandria LaunchLabsNew York VenturesBioAdvanceRemiges Ventures

Beyond the preview

Go deeper on ENB Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENB Therapeutics.

Explore the full profile